ST PAUL, Minn.--(BUSINESS WIRE)--MD Biosciences, a Preclinical Contract Research Organization (CRO), announces today that it has expanded its preclinical contract research services by launching a line of in vivo models for the study of myocardial infarct and vascular disease. These models enable the evaluation of drug treatment for myocardial infarct.
